Results 81 to 90 of about 1,626,261 (197)

Long-acting amylin analogues for the management of obesity

open access: yes, 2022
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight ...
Mathiesen, David S.   +5 more
core   +1 more source

Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke

open access: yesBrain and Behavior, Volume 16, Issue 11, November 2026.
In MEPS 2017'2023, 2,241 person‐years represented approximately 3.05 million U.S. adults with diabetes and a history of stroke annually. Survey‐weighted use of GLP‐1RAs or SGLT2 inhibitors increased from 8.7% to 33.8% (OR per year, 1.36; P < 0.001). Stroke‐history associations with insulin and metformin use attenuated after clinical adjustment and did ...
Yaojie Cai, Yu‐Jun Xiong, Tian Lv
wiley   +1 more source

Amylin, CGRP and the AMY1 receptor: Localisation in the trigeminal ganglia and receptor regulation

open access: yes, 2022
Calcitonin gene-related peptide (CGRP) is a neuromodulatory peptide that is highly expressed in the nervous system. It is involved in several physiological and pathophysiological processes, including pain and migraine.
Rees, Tayla Anne
core  

Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang   +6 more
wiley   +1 more source

Amylin: Pharmacology, Physiology, and Clinical Potential [PDF]

open access: yes, 2015
Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago.
Roth, Jonathan D   +9 more
core   +1 more source

Study of Cgrp-Receptors in Human Isolated Middle Meningeal Arteries Using Bibn4096Bs, Compound 1, and HαCgrp(8-37)

open access: yesThe Scientific World Journal, 2001
Calcitonin, CGRP, adrenomedullin, and amylin require both CRLR (calcitonin-gene receptor like receptor) and receptor activity modifying proteins (RAMP1, RAMP2, and RAMP3) in different combinations for expression of selective, functional receptors[1].
Z. Razzaque   +6 more
doaj   +1 more source

Protecting CEACAM1 Expression Prevents Diet‐Induced Metabolic Dysfunction and Hepatic Fibrosis in Male Mice

open access: yesObesity, Volume 34, Issue 11, Page 2094-2108, November 2026.
ABSTRACT Objective High‐fat diet represses Ceacam1 transcription via a PPARα‐mediated mechanism to cause insulin resistance before inflammation develops. The current study investigated whether mutating PPRE‐RXRα in Ceacam1 promoter prevents diet‐induced metabolic abnormalities and hepatic fibrosis in male C57BL6/J mice.
Raziyeh Abdolahipour   +9 more
wiley   +1 more source

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]

open access: yesMetabol Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Lempesis IG, Dalamaga M.
europepmc   +2 more sources

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context

open access: yesEBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas   +11 more
doaj   +1 more source

The gut-brain axis and alcohol-mediated behaviours: the amylin story [PDF]

open access: yes, 2018
Alcohol use disorder (AUD) is a complex neuropsychiatric disorder with high rates of mortality and morbidity. The currently available pharmacotherapies show varied efficacy, leading to the investigation of new neurochemical targets for alcohol ...
Kalafateli, Aimilia Lydia   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy